Literature DB >> 9404904

Multicenter, randomized study comparing levofloxacin and ciprofloxacin for uncomplicated skin and skin structure infections.

R L Nichols1, J W Smith, L O Gentry, J Gezon, T Campbell, P Sokol, R R Williams.   

Abstract

BACKGROUND: The fluoroquinolone, levofloxacin, is active against most common pathogens in skin and skin structure infections.
METHODS: The efficacy, tolerability, and safety of levofloxacin and ciprofloxacin were compared in a randomized, open-label, multicenter trial of patients with uncomplicated skin and skin structure infections. Of 469 patients treated, 231 received levofloxacin (500 mg qd) and 238 were given ciprofloxacin (500 mg bid).
RESULTS: Overall clinical success rates (cured plus improved) for levofloxacin and ciprofloxacin were 98% and 94%, respectively (95% confidence interval [CI], -7.7, 0.7). Overall microbiologic eradication rates by patient were 98% in the levofloxacin group and 89% in the ciprofloxacin group (95% CI, -14.5, -2.7), whereas eradication rates by pathogen were 98% and 90%, respectively (95% CI, -12.6, -3.7). The eradication rate for Staphylococcus aureus was 100% in the levofloxacin group and 87% in the ciprofloxacin group (95% CI, -20.2, -5.1). Treatment-emergent adverse events were comparable, with drug-related adverse events reported in 6% of levofloxacin patients and 5% of ciprofloxacin patients.
CONCLUSIONS: Levofloxacin is as effective and safe as ciprofloxacin in the treatment of uncomplicated skin and skin structure infections.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9404904     DOI: 10.1097/00007611-199712000-00006

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  16 in total

1.  Are Respiratory Quinolones Useful for the Treatment of Skin and Soft Tissue Infections?

Authors:  James S. Tan
Journal:  Curr Infect Dis Rep       Date:  2003-10       Impact factor: 3.725

Review 2.  Potential interactions of the extended-spectrum fluoroquinolones with the CNS.

Authors:  H Lode
Journal:  Drug Saf       Date:  1999-08       Impact factor: 5.606

3.  Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers.

Authors:  S C Chien; F A Wong; C L Fowler; S V Callery-D'Amico; R R Williams; R Nayak; A T Chow
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

4.  Safety and pharmacokinetics of multiple 750-milligram doses of intravenous levofloxacin in healthy volunteers.

Authors:  A T Chow; C Fowler; R R Williams; N Morgan; S Kaminski; J Natarajan
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

5.  The new fluoroquinolones: A critical review.

Authors:  G G Zhanel; A Walkty; L Vercaigne; J A Karlowsky; J Embil; A S Gin; D J Hoban
Journal:  Can J Infect Dis       Date:  1999-05

Review 6.  A practical guide to the treatment of complicated skin and soft tissue infections.

Authors:  Horatio B Fung; Joanne Y Chang; Stephen Kuczynski
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 7.  Newer treatment options for skin and soft tissue infections.

Authors:  Murugan Raghavan; Peter K Linden
Journal:  Drugs       Date:  2004       Impact factor: 9.546

8.  The Role of Fluoroquinolones in the Treatment of Skin and Soft Tissue Infection.

Authors:  Md Rabiul Alam; Ellie Hershberger; Marcus J. Zervos
Journal:  Curr Infect Dis Rep       Date:  2002-10       Impact factor: 3.725

Review 9.  Levofloxacin: a review of its use in the treatment of bacterial infections in the United States.

Authors:  Katherine F Croom; Karen L Goa
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 10.  Levofloxacin: an updated review of its use in the treatment of bacterial infections.

Authors:  Miriam Hurst; Harriet M Lamb; Lesley J Scott; David P Figgitt
Journal:  Drugs       Date:  2002       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.